logo

For the Inventor, By the Inventor

Marburg, Germany

Volkmar Gunzler

This inventor holds 12 USPTO granted patents. Top assignee: Hoechst Aktiengesellschaft. Active years: 1988-1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Volkmar Gunzler. Retrieved from https://idiyas.com/inventor/volkmar-gunzler

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12

% Patents Active = 100.0

Average Co-Inventor Count = 5.7

ph-index = 4

Forward Citations = 74(Granted Patents)


Location History:

  • Bodenheim, DE (1988)
  • Marburg-Cappel, DE (1989 - 1997)

Company Filing History:

goldMedal12 out of 6,705 
 
Hoechst Aktiengesellschaft
 patents

Years Active: 1988-1997

Loading Chart...
12 patents (USPTO):Explore Patents
1. 5672614 - Pharmaceutical use of pyridine-2,4- and -2,5-dicarboxylic acid amides (1997-09-30),
2. 5512586 - Medicaments based on pyridine-2,4- and 2,5-dicarboxylic acid amides (1996-04-30),
3. 5422342 - 2,3-disubstituted isoxazolidines, agents containing them and their use (1995-06-06),
4. 5356909 - Substituted pyridine-2,4-dicarboxylic acid compounds and the use thereof (1994-10-18),
5. 5238948 - Pyridine-2,4- and -2,5-dicarboxylic acid derivatives and medicaments (1993-08-24),
6. 5153208 - Pyridine-2,4- and -2,5-dicarboxylic acid amides and their medicinal (1992-10-06),
7. 5143926 - Substituted pyridine-2,4-dicarboxylic acid compounds and methods of use (1992-09-01),
8. 5037839 - Pyridine-2,4-and -2,5-dicarboxylic acid amides and medicaments based on (1991-08-06),
9. 5004748 - Substituted pyridine-2,4-dicarboxylic acid derivatives and medicaments (1991-04-02),
10. 4968670 - Pyridine-2,4- and 2,5-dicarboxylic acid derivatives, a process for their (1990-11-06),
11. 4797471 - Peptide derivatives having an inhibitory action on hydroxylating (1989-01-10),
12. 4717727 - Esters of pyridine-2,4- and 2,5-dicarboxylic acid as medicaments for the (1988-01-05),

Title: The Innovative Contributions of Volkmar Gunzler

Introduction

Volkmar Gunzler, an accomplished inventor based in Marburg-Cappel, Germany, has made significant contributions in the field of pharmaceuticals. With a total of 12 patents to his name, Gunzler's work focuses on the development of compounds that have the potential to impact health and medicine positively.

Latest Patents

Among his latest innovations are the patents related to the pharmaceutical use of pyridine-2,4- and -2,5-dicarboxylic acid amides. These patents describe a series of pyridine-2,4- and -2,5-dicarboxylic acid derivatives, which have specific applications in the preparation of medicaments. These compounds are designed to influence the metabolism of collagen and collagen-like substances or the biosynthesis of Cl.q. This research holds promise for advancements in medical treatments and therapies.

Career Highlights

Volkmar Gunzler has built a noteworthy career, primarily associated with Hoechst Aktiengesellschaft, a leading global pharmaceutical company. His innovative spirit and dedication to research have cemented his reputation as a prominent figure in the field of medicinal chemistry and pharmacology.

Collaborations

Throughout his career, Gunzler has collaborated with several prominent professionals, including Dietrich Brocks and Hartmut Hanauske-Abel. These partnerships have enabled the exchange of ideas and fostered a collaborative environment that encourages further innovation in pharmaceutical research.

Conclusion

Volkmar Gunzler stands out as an influential inventor whose work in developing pharmaceutical compounds has the potential to revolutionize treatment options in medicine. His dedication to research and collaboration aligns with the ongoing pursuit of innovation in the healthcare sector, making his contributions invaluable to the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…